OHR Pharmaceutical Inc (OHRP) : Garrison Bradford Associates Inc reduced its stake in OHR Pharmaceutical Inc by 1.1% during the most recent quarter end. The investment management company now holds a total of 90,200 shares of OHR Pharmaceutical Inc which is valued at $257,972 after selling 1,000 shares in OHR Pharmaceutical Inc , the firm said in a disclosure report filed with the SEC on Aug 2, 2016.OHR Pharmaceutical Inc makes up approximately 0.24% of Garrison Bradford Associates Inc’s portfolio.
Other Hedge Funds, Including , Simplex Trading added OHRP to its portfolio by purchasing 6,327 company shares during the most recent quarter which is valued at $15,944.Creative Planning boosted its stake in OHRP in the latest quarter, The investment management firm added 5,400 additional shares and now holds a total of 11,500 shares of OHR Pharmaceutical Inc which is valued at $31,050.Cutler Group Lp boosted its stake in OHRP in the latest quarter, The investment management firm added 3,400 additional shares and now holds a total of 24,685 shares of OHR Pharmaceutical Inc which is valued at $66,650.
OHR Pharmaceutical Inc closed down -0.1 points or -3.73% at $2.58 with 56,383 shares getting traded on Monday. Post opening the session at $2.68, the shares hit an intraday low of $2.57 and an intraday high of $2.7063 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
Many Wall Street Analysts have commented on OHR Pharmaceutical Inc. ROTH Capital Resumed OHR Pharmaceutical Inc on Jun 16, 2016 to “Buy”, Price Target of the shares are set at $13.
Ohr Pharmaceutical Inc. is a pharmaceutical company. The Company is focusing on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company’s development pipeline consists of various programs and indications at various stages of development. The Company’s clinical program OHR-102 eye drops is a therapeutic product that provides a non-invasive therapy to improve vision outcomes without requiring multiple injections per office visit. The Company focuses on OHR-102 eye drops which is given in combination with Lucentis injections for the treatment of retinal diseases including wet-age-related macular degeneration (AMD) retinal vein occlusion and proliferative diabetic retinopathy. The Company’s product pipeline also includes SKS Sustained Release Ocular Drug Delivery Platform Technology Animal Model for Dry-AMD and Non-Ophthalmology Assets. OHR-102 is a small molecule anti-angiogenic drug with an intracellular mechanism of action.